- Home
- FRD vs EQ Comparison
FRD vs EQ Comparison
Compare FRD & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRD | EQ |
|---|---|---|
| Founded | 1965 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 129.0M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FRD | EQ |
|---|---|---|
| Price | $20.64 | $2.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 22.4K | ★ 252.6K |
| Earning Date | 06-11-2026 | 05-25-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.02 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $14.52 | $0.29 |
| 52 Week High | $24.37 | $2.70 |
Technical Indicators
Market Signals| Indicator | FRD | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 53.74 | 53.44 |
| Support Level | $20.54 | $1.60 |
| Resistance Level | $22.76 | $2.61 |
| Average True Range (ATR) | 1.01 | 0.24 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 33.39 | 52.54 |
Price Performance
Historical ComparisonAbout FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.